papillary RCC

• 

Bevacizumab plus erlotinib shows antitumor activity in advanced papillary kidney cancer

By Sharon Deveson Kell|2025-10-07T08:32:56+00:007 Oct 2025|Drug treatments|

A recent phase 2 study, published in the New England [...]

Read More

Comments Off on Bevacizumab plus erlotinib shows antitumor activity in advanced papillary kidney cancer

• 

Combination therapy shows promise for hereditary papillary kidney cancer

By Sharon Deveson Kell|2025-06-20T15:30:06+00:0020 Jun 2025|Drug treatments|

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated papillary RCC is [...]

Read More

Comments Off on Combination therapy shows promise for hereditary papillary kidney cancer

• 

Immunotherapy for the treatment of non-clear cell kidney cancer

By Sharon Deveson Kell|2025-04-28T07:56:33+00:0028 Apr 2025|Drug treatments|

There are several types of kidney cancer, the most common [...]

Read More

Comments Off on Immunotherapy for the treatment of non-clear cell kidney cancer

• 

Immunotherapy combinations versus TKIs for papillary renal cell carcinoma

By Sharon Deveson Kell|2024-04-12T07:29:29+00:0012 Apr 2024|Drug treatments|

Papillary renal cell carcinoma (pRCC) is the most common subtype [...]

Read More

Comments Off on Immunotherapy combinations versus TKIs for papillary renal cell carcinoma

• 

Pembrolizumab plus lenvatinib for non-clear cell kidney cancer

By Sharon Deveson Kell|2023-10-02T08:53:12+00:002 Oct 2023|Drug treatments|

Immunotherapy combinations are becoming the standard treatment for people with [...]

Read More

Comments Off on Pembrolizumab plus lenvatinib for non-clear cell kidney cancer

• 

Savolitinib and durvalumab for metastatic papillary kidney cancer

By Sharon Deveson Kell|2023-03-23T09:27:27+00:0023 Mar 2023|Drug treatments|

In a phase 2 clinical trial, patients with metastatic papillary [...]

Read More

Comments Off on Savolitinib and durvalumab for metastatic papillary kidney cancer

• 

Savolitinib plus durvalumab for papillary kidney cancer

By Sharon Deveson Kell|2023-03-06T12:34:35+00:006 Mar 2023|Drug treatments|

In a recent study published in the Journal of Clinical [...]

Read More

Comments Off on Savolitinib plus durvalumab for papillary kidney cancer

• 

Real-world survival outcomes of metastatic papillary and clear cell kidney cancer

By Sharon Deveson Kell|2023-01-17T08:22:55+00:0017 Jan 2023|Drug treatments|

In this study, real world data is used to compare [...]

Read More

Comments Off on Real-world survival outcomes of metastatic papillary and clear cell kidney cancer

• 

Papillary type I vs type II renal cell carcinoma

By Sharon Deveson Kell|2022-06-28T08:44:46+00:0028 Jun 2022|Subtypes of RCC|

Papillary renal cell carcinoma (pRCC) is the second most common [...]

Read More

Comments Off on Papillary type I vs type II renal cell carcinoma

• 

EIKCS 2022: Treatment for non-clear cell kidney cancer subtypes

By Sharon Deveson Kell|2022-04-26T08:39:32+00:0026 Apr 2022|Drug treatments, Subtypes of RCC|

At the European International Kidney Cancer Symposium (EIKCS) in Antwerp, [...]

Read More

Comments Off on EIKCS 2022: Treatment for non-clear cell kidney cancer subtypes